Incmor00208
WebDec 17, 2024 · Name: Incyte Corporation Call Center (US) Phone Number: 1.855.463.3463 Email: [email protected] Study Contact Backup Name: Incyte Corporation Call Center … WebINCMOR00208; MOR00208; Drug: rituximab Rituximab will be administered IV on cycles 1 - 5; Drug: lenalidomide Lenalidomide will be administered PO for 12 cycles; Placebo …
Incmor00208
Did you know?
WebJan 11, 2024 · This is an open-label, multicentre study too Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) who have had at least one, but no more than three prior systemic regimens … WebJun 23, 2024 · INCMOR00208; MOR00208; Drug: Lenalidomide. Participants will self-administer lenalidomide capsules orally on Days 1-21 of each 28-day cycle, up to 12 …
Web【INCMOR00208】 (注射剤、抗CD19抗体薬) A群：tafasitamab+リツキシマブ+レナリドミド B群：プラセボ+リツキシマブ+レナリドミド: III: 588: 再発/難治性濾胞性リンパ腫(FL) 再発/難治性びまん性大細胞型B細胞性リンパ腫(DLBCL) CD3、CD20 ・odronextamab … Web治験・臨床研究に関する相談窓口. 〒650-0047. 神戸市中央区港島南町2丁目1番地1. 臨床研究推進センター. TEL：（078）302-4448 ※電話応対は平日9:00〜17:00. FAX：（078）302-4604. メール：c_ccri1あっとkcho.jp. ※迷惑メール対策のため、メールアドレスの あっと …
Web四国がんセンターで実施している治験等 (医師主導治験を含む) (2024年2月6日現在) 現在募集中の治験の情報を掲載しています。. 掲載している情報は定期的に更新を行っていますが、常に最新の内容が掲載されているわけではありません。. 治験の進行状況に ... Webtafasitamab, INCMOR00208, MOR00208, Xmab5574, lenalidomide, parsaclisib, R-CHOP Incyte Biosciences Japan GK Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma
WebInMIND, NCT04680052 / 2024-004407-13: A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or …
WebINCMOR 0208-301 NCT ID: NCT04680052 Conditions Follicular Lymphoma Marginal Zone Lymphoma Interventions Purpose This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamaband lenalidomideas an add-on to rituximabprovides improved clinical how far is newburgh indiana to louisville kyWebDec 22, 2024 · INCMOR00208; MOR00208; Drug: rituximab Rituximab will be administered IV on cycles 1 - 5. Drug: lenalidomide Lenalidomide will be administered PO for 12 cycles. … high boundlessWebTrial + Data / Events Status Ph N Region Interventions Sponsor Conditions Primary compl Study compl; Monjuvi how far is new brunswick nj from meWebDec 9, 2024 · INCMOR00208; MOR00208; Xmab5574; Drug: parsaclisib parsaclisib will be administered at protocol defined timepoints based on the groups participants are … high bouncy chairWebMar 19, 2024 · The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to evaluate whether tafasitamab and parsaclisib can be safely combined at the recommended Phase 2 dose (RP2D) and dosing regimen that was established for each of the 2 compounds as a treatment option for adult participants with R/R B-cell malignancies. high bouncy ballsWebDec 1, 2024 · INCMOR00208; Xmab5574; Experimental: Part 2 : tafasitamab combination therapy . tafasitamab will be combined with lenalidomide (Group 3) or parsaclisib (Group … how far is newbury nh from nashua nhWebDec 1, 2024 · The dose of tafasitamab will be based on the weight-based RP2D that is deemed safe and tolerable in Part 1. Experimental: Part 3 : Dose Expansion of tafasitamab +parsaclisib. tafasitamab in combination with parsaclisib will be further evaluated in Group 4b at RP2D determined in Part 2. Experimental: Part 4: tafasitamab combination therapy. high boundary